Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.64
WBA's Cash-to-Debt is ranked higher than
55% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.51 vs. WBA: 0.64 )
Ranked among companies with meaningful Cash-to-Debt only.
WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.26 Max: No Debt
Current: 0.64
Equity-to-Asset 0.41
WBA's Equity-to-Asset is ranked lower than
52% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. WBA: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.55 Max: 0.64
Current: 0.41
0.41
0.64
Debt-to-Equity 0.63
WBA's Debt-to-Equity is ranked lower than
56% of the 301 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. WBA: 0.63 )
Ranked among companies with meaningful Debt-to-Equity only.
WBA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 0.7
Current: 0.63
0
0.7
Debt-to-EBITDA 2.64
WBA's Debt-to-EBITDA is ranked lower than
54% of the 296 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.38 vs. WBA: 2.64 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WBA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.23  Med: 0.69 Max: 2.64
Current: 2.64
0.23
2.64
Interest Coverage 8.32
WBA's Interest Coverage is ranked lower than
71% of the 331 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.52 vs. WBA: 8.32 )
Ranked among companies with meaningful Interest Coverage only.
WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.72  Med: 39.24 Max: No Debt
Current: 8.32
Piotroski F-Score: 7
Altman Z-Score: 3.49
Beneish M-Score: -2.82
WACC vs ROIC
6.96%
11.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 4.78
WBA's Operating Margin % is ranked higher than
69% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. WBA: 4.78 )
Ranked among companies with meaningful Operating Margin % only.
WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.51  Med: 5.31 Max: 6.05
Current: 4.78
4.51
6.05
Net Margin % 3.69
WBA's Net Margin % is ranked higher than
72% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.98 vs. WBA: 3.69 )
Ranked among companies with meaningful Net Margin % only.
WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.55 Max: 4.08
Current: 3.69
2.53
4.08
ROE % 14.28
WBA's ROE % is ranked higher than
71% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.10 vs. WBA: 14.28 )
Ranked among companies with meaningful ROE % only.
WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.63 Max: 19.24
Current: 14.28
9.67
19.24
ROA % 6.00
WBA's ROA % is ranked higher than
69% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.68 vs. WBA: 6.00 )
Ranked among companies with meaningful ROA % only.
WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 8.05 Max: 11.2
Current: 6
5.31
11.2
ROC (Joel Greenblatt) % 39.31
WBA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.54 vs. WBA: 39.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 29.67 Max: 39.31
Current: 39.31
24.31
39.31
3-Year Revenue Growth Rate 12.50
WBA's 3-Year Revenue Growth Rate is ranked higher than
80% of the 346 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.90 vs. WBA: 12.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 12.5 Max: 16.5
Current: 12.5
0.5
16.5
3-Year EBITDA Growth Rate 7.90
WBA's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 317 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. WBA: 7.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 12.3 Max: 18.3
Current: 7.9
-1.1
18.3
3-Year EPS without NRI Growth Rate 12.70
WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. WBA: 12.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 14.1 Max: 20
Current: 12.7
-12.1
20
GuruFocus has detected 6 Warning Signs with Walgreens Boots Alliance Inc WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WBA's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

WBA Guru Trades in Q3 2016

Joel Greenblatt 831,783 sh (+76.83%)
Pioneer Investments 229,753 sh (+31.03%)
Ken Fisher 6,726 sh (+4.30%)
First Pacific Advisors 86,550 sh (+2.61%)
Mario Gabelli 451,894 sh (+0.40%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
George Soros 25,558 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Dodge & Cox 8,579 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
John Griffin 1,681,000 sh (unchged)
Mairs and Power 11,445 sh (unchged)
Jim Simons Sold Out
Jana Partners Sold Out
Leon Cooperman 1,086,300 sh (-11.17%)
Andreas Halvorsen 1,191,911 sh (-65.65%)
Paul Tudor Jones 6,506 sh (-79.20%)
» More
Q4 2016

WBA Guru Trades in Q4 2016

Larry Robbins 1,500,000 sh (New)
Jim Simons 1,928,300 sh (New)
Andreas Halvorsen 7,899,951 sh (+562.80%)
Paul Tudor Jones 34,315 sh (+427.44%)
Ken Fisher 7,811 sh (+16.13%)
Mairs and Power 13,045 sh (+13.98%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
George Soros Sold Out
John Griffin Sold Out
First Pacific Advisors Sold Out
Mario Gabelli 450,379 sh (-0.34%)
Dodge & Cox 8,079 sh (-5.83%)
Leon Cooperman 934,100 sh (-14.01%)
Joel Greenblatt 687,941 sh (-17.29%)
Pioneer Investments 182,995 sh (-20.35%)
» More
Q1 2017

WBA Guru Trades in Q1 2017

Lee Ainslie 1,013,553 sh (New)
Steven Cohen 327,100 sh (New)
Ray Dalio 20,187 sh (New)
Andreas Halvorsen 12,063,404 sh (+52.70%)
Paul Tudor Jones 38,334 sh (+11.71%)
Mairs and Power 14,364 sh (+10.11%)
Pioneer Investments 186,947 sh (+2.16%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Larry Robbins Sold Out
Mario Gabelli 444,614 sh (-1.28%)
Dodge & Cox 7,569 sh (-6.31%)
Ken Fisher 7,155 sh (-8.40%)
Leon Cooperman 826,103 sh (-11.56%)
Joel Greenblatt 330,643 sh (-51.94%)
Jim Simons 23,100 sh (-98.80%)
» More
Q2 2017

WBA Guru Trades in Q2 2017

John Hussman 50,000 sh (New)
Larry Robbins 1,747,858 sh (New)
John Buckingham 12,237 sh (New)
Ray Dalio 62,547 sh (+209.84%)
Jim Simons 51,300 sh (+122.08%)
Paul Tudor Jones 68,703 sh (+79.22%)
Joel Greenblatt 566,818 sh (+71.43%)
Mairs and Power 15,916 sh (+10.80%)
Mario Gabelli 464,409 sh (+4.45%)
Tom Gayner 2,135,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Dodge & Cox 7,569 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Ken Fisher 7,134 sh (-0.29%)
Pioneer Investments 169,248 sh (-9.47%)
Andreas Halvorsen 3,012,489 sh (-75.03%)
Lee Ainslie 251,710 sh (-75.17%)
» More
» Details

Insider Trades

Latest Guru Trades with WBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 71.43%0.26%$76.34 - $86.54 $ 67.40-18%566,818
Mario Gabelli 2017-06-30 Add 4.45%0.01%$76.34 - $86.54 $ 67.40-18%464,409
Ken Fisher 2017-06-30 Reduce -0.29%$76.34 - $86.54 $ 67.40-18%7,134
Leon Cooperman 2017-06-30 Sold Out 2.76%$76.34 - $86.54 $ 67.40-18%0
Leon Cooperman 2017-03-31 Reduce -11.56%0.39%$80.47 - $87.61 $ 67.40-20%826,103
Mario Gabelli 2017-03-31 Reduce -1.28%$80.47 - $87.61 $ 67.40-20%444,614
Joel Greenblatt 2017-03-31 Reduce -51.94%0.38%$80.47 - $87.61 $ 67.40-20%330,643
Dodge & Cox 2017-03-31 Reduce -6.31%$80.47 - $87.61 $ 67.40-20%7,569
Ken Fisher 2017-03-31 Reduce -8.40%$80.47 - $87.61 $ 67.40-20%7,155
Leon Cooperman 2016-12-31 Reduce -14.01%0.38%$77.18 - $87.73 $ 67.40-18%934,100
Joel Greenblatt 2016-12-31 Reduce -17.29%0.15%$77.18 - $87.73 $ 67.40-18%687,941
Mario Gabelli 2016-12-31 Reduce -0.34%$77.18 - $87.73 $ 67.40-18%450,379
Dodge & Cox 2016-12-31 Reduce -5.83%$77.18 - $87.73 $ 67.40-18%8,079
Ken Fisher 2016-12-31 Add 16.13%$77.18 - $87.73 $ 67.40-18%7,811
George Soros 2016-12-31 Sold Out 0.08%$77.18 - $87.73 $ 67.40-18%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:BSP:RADL3, TSE:3391, SHSE:600998, TSE:9989, TSE:3349, TSE:3141, TSE:3088, TSX:PJC.A, TSE:7649, JSE:CLS, SSE:2928, TSE:9627, NYSE:RAD, SHSE:603883, SHSE:603939, JSE:DCP, TSE:3549, TSE:3148, SZSE:002727, TSE:3098 » details
Traded in other countries:WBA.Austria, W8A.Germany, WBA.Mexico, WBA.Switzerland, 0R0C.UK,
Headquarter Location:USA
Walgreens Boots Alliance Inc operates pharmacy store chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug stores, as well as mail, and by telephone and online.

Walgreens is one of the nation's largest retail pharmacies, with about 8,175 drugstores throughout the United States. The firm recently acquired half of Rite Aid's locations, which will push its store count to approximately 10,000. This large network of stores enables the firm to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items.

Top Ranked Articles about Walgreens Boots Alliance Inc

52-Week Company Lows Prices fall for shares of General Electric, Kraft Heinz, Walgreens, General Mills, Kellogg and Molson Coors
According to GuruFocus’ list, these stocks have reached their 52-week lows. Read more...
Examining Consolidated Results on Allergan, Starbucks, Equifax, Walgreens, Texas Instruments, and Kraft Heinz – Fundamental Analysis and Changes in Performance Indicators
Rite Aid Plummets on Weak Quarterly Sales, Revenue Following failed takeover, FTC approved the sale of 1,932 stores to Walgreens last week
Drugstore chain Rite Aid Corp. (NYSE:RAD) reported its second-quarter 2018 results before the opening bell on Sept. 28. Read more...
Should you buy Apple, Capital One, 3D Systems, AT&T or Walgreens Boots Alliance?
Walgreens Donates Funds to Support the CDC Foundation's Sustainable Healthcenter Implementation PrEP Pilot (SHIPP) Study
Introducing CYO Cosmetics, A Hyper-Functional, Multi-Tasking Makeup Line That Lets You #MixLayerHack™ Your Look
John Buckingham Picks Up 4 Retailers in 2nd Quarter Guru invests in Walgreens, Kroger, Amazon and Home Depot
AFAM Capital’s John Buckingham (Trades, Portfolio) established 18 new holdings during the second quarter, four of which were in retailers. Read more...
What Doesn’t Kill You Makes You Stronger We believe the lack of enthusiasm for stocks and today’s set of circumstances provide a blueprint to future profits in US large-cap stocks
A few years ago, there was a TV commercial for the Toyota Camry featuring singer Kelly Clarkson and ESPN’s legendary sportscaster Chris Berman. It pointed out all the positive attributes of the new car with Clarkson’s hit, “Stronger,” playing in the background. As we look out into the second half of 2017, it is important to understand we believe the U.S. stock market has tried to “kill” investor enthusiasm. We would argue this enhances the position of the value-oriented and long duration equity manager in a way that does not kill us but makes us "stronger." Read more...
Introducing the Stock Screen That Tells You Companies With Recently Released Earnings GuruFocus developers release the 'Most Recent Financial Update' feature just in time for earnings season
Developers at GuruFocus today added a new feature to the All-in-One Screener that makes keeping tabs on companies’ earnings releases easier. Read more...
Options Trades: covered-call reports for Cisco Systems, Facebook, Procter & Gamble, Walgreens Boots Alliance and Walmart Stores Inc.

Ratios

vs
industry
vs
history
PE Ratio 17.01
WBA's PE Ratio is ranked higher than
50% of the 305 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.33 vs. WBA: 17.01 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 19.18 Max: 35.8
Current: 17.01
10.2
35.8
Forward PE Ratio 12.24
WBA's Forward PE Ratio is ranked higher than
74% of the 65 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.08 vs. WBA: 12.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.01
WBA's PE Ratio without NRI is ranked higher than
52% of the 307 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.07 vs. WBA: 17.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 19.18 Max: 35.8
Current: 17.01
10.2
35.8
Price-to-Owner-Earnings 10.74
WBA's Price-to-Owner-Earnings is ranked higher than
72% of the 216 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.15 vs. WBA: 10.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WBA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.76  Med: 15.58 Max: 40.18
Current: 10.74
8.76
40.18
PB Ratio 2.36
WBA's PB Ratio is ranked lower than
63% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.85 vs. WBA: 2.36 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.74 Max: 4.6
Current: 2.36
1.6
4.6
PS Ratio 0.63
WBA's PS Ratio is ranked lower than
65% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. WBA: 0.63 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.65 Max: 1.08
Current: 0.63
0.36
1.08
Price-to-Free-Cash-Flow 11.16
WBA's Price-to-Free-Cash-Flow is ranked higher than
65% of the 159 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.63 vs. WBA: 11.16 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.87  Med: 17.17 Max: 103.55
Current: 11.16
9.87
103.55
Price-to-Operating-Cash-Flow 9.26
WBA's Price-to-Operating-Cash-Flow is ranked lower than
54% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.46 vs. WBA: 9.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.43  Med: 11.33 Max: 20.71
Current: 9.26
6.43
20.71
EV-to-EBIT 14.33
WBA's EV-to-EBIT is ranked lower than
57% of the 316 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.23 vs. WBA: 14.33 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 12.8 Max: 25.1
Current: 14.33
6.3
25.1
EV-to-EBITDA 10.99
WBA's EV-to-EBITDA is ranked lower than
53% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.89 vs. WBA: 10.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 10.1 Max: 18.8
Current: 10.99
4.9
18.8
EV-to-Revenue 0.68
WBA's EV-to-Revenue is ranked lower than
64% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.60 vs. WBA: 0.68 )
Ranked among companies with meaningful EV-to-Revenue only.
WBA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 1.3
Current: 0.68
0.4
1.3
PEG Ratio 4.25
WBA's PEG Ratio is ranked lower than
78% of the 182 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. WBA: 4.25 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.75 Max: 8.78
Current: 4.25
0.5
8.78
Shiller PE Ratio 22.81
WBA's Shiller PE Ratio is ranked lower than
62% of the 89 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.98 vs. WBA: 22.81 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.88  Med: 24.73 Max: 41.68
Current: 22.81
13.88
41.68
Current Ratio 1.30
WBA's Current Ratio is ranked higher than
56% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. WBA: 1.30 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.66 Max: 2.36
Current: 1.3
1.19
2.36
Quick Ratio 0.90
WBA's Quick Ratio is ranked higher than
62% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.74 vs. WBA: 0.90 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 1.7
Current: 0.9
0.27
1.7
Days Inventory 38.14
WBA's Days Inventory is ranked higher than
51% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.32 vs. WBA: 38.14 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 53.52 Max: 60.84
Current: 38.14
35.11
60.84
Days Sales Outstanding 19.83
WBA's Days Sales Outstanding is ranked lower than
58% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.08 vs. WBA: 19.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.78 Max: 24.17
Current: 19.83
11.04
24.17
Days Payable 47.97
WBA's Days Payable is ranked higher than
57% of the 273 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 42.45 vs. WBA: 47.97 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 48.01
Current: 47.97
28.73
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.26
WBA's Dividend Yield % is ranked higher than
54% of the 492 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.98 vs. WBA: 2.26 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.61  Med: 1.74 Max: 3.11
Current: 2.26
0.61
3.11
Dividend Payout Ratio 0.38
WBA's Dividend Payout Ratio is ranked higher than
59% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. WBA: 0.38 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.31 Max: 0.64
Current: 0.38
0.16
0.64
3-Year Dividend Growth Rate 8.50
WBA's 3-Year Dividend Growth Rate is ranked higher than
51% of the 189 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.20 vs. WBA: 8.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 13.7 Max: 26
Current: 8.5
3.8
26
Forward Dividend Yield % 2.38
WBA's Forward Dividend Yield % is ranked lower than
52% of the 466 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.05 vs. WBA: 2.38 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.31
WBA's 5-Year Yield-on-Cost % is ranked higher than
66% of the 516 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.05 vs. WBA: 4.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.16  Med: 3.32 Max: 5.94
Current: 4.31
1.16
5.94
3-Year Average Share Buyback Ratio -4.60
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 220 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. WBA: -4.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.9  Med: 0 Max: 3.5
Current: -4.6
-4.9
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.78
WBA's Price-to-Tangible-Book is ranked lower than
94% of the 330 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. WBA: 14.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.94  Med: 3.98 Max: 58.76
Current: 14.78
1.94
58.76
Price-to-Intrinsic-Value-Projected-FCF 1.05
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 225 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. WBA: 1.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 2.58 Max: 18.64
Current: 1.05
0.73
18.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.43
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
58% of the 60 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.43 vs. WBA: 1.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WBA' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.55  Med: 1.31 Max: 2.92
Current: 1.43
0.55
2.92
Price-to-Median-PS-Value 0.97
WBA's Price-to-Median-PS-Value is ranked higher than
50% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. WBA: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.11 Max: 3.19
Current: 0.97
0.56
3.19
Price-to-Peter-Lynch-Fair-Value 2.71
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 110 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.68 vs. WBA: 2.71 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.94 Max: 6.3
Current: 2.71
0.57
6.3
Price-to-Graham-Number 3.34
WBA's Price-to-Graham-Number is ranked lower than
89% of the 256 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.46 vs. WBA: 3.34 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WBA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 2.02 Max: 8.07
Current: 3.34
0.99
8.07
Earnings Yield (Greenblatt) % 6.96
WBA's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.84 vs. WBA: 6.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 7.8 Max: 15.9
Current: 6.96
4
15.9
Forward Rate of Return (Yacktman) % 12.60
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
65% of the 252 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.34 vs. WBA: 12.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7  Med: 14 Max: 23.7
Current: 12.6
7
23.7

More Statistics

Revenue (TTM) (Mil) $116,701.00
EPS (TTM) $ 3.96
Beta0.93
Short Percentage of Float2.32%
52-Week Range $67.21 - 88.00
Shares Outstanding (Mil)1,070.10

Analyst Estimate

Aug17 Aug18 Aug19
Revenue (Mil $) 117,638 126,580 138,032
EPS ($) 4.96 5.32 6.00
EPS without NRI ($) 4.96 5.32 6.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.10%
Dividends per Share ($) 1.49 1.56 1.73

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}